



(86) **Date de dépôt PCT/PCT Filing Date:** 2010/06/25
(87) **Date publication PCT/PCT Publication Date:** 2011/12/29
(45) **Date de délivrance/Issue Date:** 2018/06/05
(85) **Entrée phase nationale/National Entry:** 2012/11/21
(86) **N° demande PCT/PCT Application No.:** IB 2010/001911
(87) **N° publication PCT/PCT Publication No.:** 2011/161491

(51) **Cl.Int./Int.Cl. A61K 38/16** (2006.01),
A61P 11/00 (2006.01), **A61P 31/04** (2006.01)

(72) **Inventeurs/Inventors:**
SIRARD, JEAN-CLAUDE, FR;
CHABALGOITY, JOSE A., UY

(73) **Propriétaires/Owners:**
(INSERM) INSTITUT NATIONAL DE LA SANTE ET DE
LA RECHERCHE MEDICALE, FR;
INSTITUT PASTEUR DE LILLE, FR

(74) **Agent:** NORTON ROSE FULBRIGHT CANADA
LLP/S.E.N.C.R.L., S.R.L.

(54) **Titre : PROCÉDES ET COMPOSITIONS PHARMACEUTIQUES POUR LE TRAITEMENT D'INFECTIONS DES VOIES
RESPIRATOIRES**

(54) **Title: METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS**

(57) **Abrégé/Abstract:**

The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
29 December 2011 (29.12.2011)

(10) International Publication Number
WO 2011/161491 A1

(51) International Patent Classification:

A61K 38/16 (2006.01) *A61P 31/04* (2006.01)
A61P 11/00 (2006.01)

(21) International Application Number:

PCT/IB2010/001911

(22) International Filing Date:

25 June 2010 (25.06.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(71) Applicants (for all designated States except US): **INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)** [FR/FR]; 101, rue de Tolbiac, F-75013 Paris (FR). **INSTITUT PASTEUR DE LILLE** [FR/FR]; 1, rue du Professeur Calmette, F-59000 Lille (FR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SIRARD, Jean-Claude** [FR/FR]; CIIL - Center for Infection and Immunity of Lille, INSERM U 1019 - CNRS UMR 8204 Univ Lille, Nord de France - Institut Pasteur de Lille, 1, rue du Professeur Calmette, F-59019 LILLE Cedex (FR). **CHABALGOITY, Jose, A.** [UY/UY]; Professor and Head of Department of Biotechnology, Instituto de Higiene, Facultad de Medicina, Avda . A . Navarro 3051, 11600 MONTEVIDEO (UY).

(74) Agent: **HIRSCH, Denise**; Inserm-Transfert, 7 rue Watt, F-75013 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))

— with sequence listing part of description (Rule 5.2(a))

(54) Title: METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS

(57) Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.



WO 2011/161491 A1

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY TRACT INFECTIONS

5 **FIELD OF THE INVENTION:**

The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.

10 **BACKGROUND OF THE INVENTION:**

Respiratory tract infections are common infections of the upper respiratory tract (e.g., nose, ears, sinuses, and throat) and lower respiratory tract (e.g., trachea, bronchial tubes, and lungs). Symptoms of upper respiratory tract infection include runny or stuffy nose, irritability, restlessness, poor appetite, decreased activity level, coughing, and fever.

15 Viral respiratory tract infections cause and/or are associated with sore throats, croup, and the flu. Examples of viruses that cause upper and lower respiratory tract infections include rhinoviruses and influenza viruses A and B.

Common respiratory bacterial infections cause and/or associated with, for example, whooping cough and strep throat. An example of a bacterium that causes upper and lower
20 respiratory tract infections is *Streptococcus pneumoniae*. *Streptococcus pneumoniae* (pneumococcus) causes respiratory tract infections among infants and the elderly worldwide. Capsular polysaccharide is the main virulence factor, and its composition defines 91 serotypes of pneumococcus. Certain serotypes colonize asymptotically the human nasopharynx representing a reservoir for inter-individual transmission of the bacteria. In some individuals
25 colonization may progress to pneumococcal pneumonia and invasive disease. In contrast, serotypes like serotype 1 are rarely associated with colonization but cause invasive infections.

Current therapies for respiratory tract infections involve the administration of anti-viral agents, anti-bacterial, and antifungal agents for the treatment, prevention, or amelioration of viral, bacterial, and fungal respiratory tract infections, respectively. Unfortunately, in
30 regard to certain infections, there are no therapies available, infections have been proven to be refractory to therapies, or the occurrence of side effects outweighs the benefits of the administration of a therapy to a subject. The use of anti-bacterial agents for treatment of bacterial respiratory tract infections may also produce side effects or result in resistant bacterial strains. The administration of antifungal agents may cause renal failure or bone

marrow dysfunction and may not be effective against fungal infection in subjects with suppressed immune systems. Additionally, the infection causing microorganism (e.g., virus, bacterium, or fungus) may be resistant or develop resistance to the administered therapeutic agent or combination of therapeutic agents. In fact, microorganisms that develop resistance to administered therapeutic agents often develop pleiotropic drug or multidrug resistance, that is, resistance to therapeutic agents that act by mechanisms different from the mechanisms of the administered agents. Thus, as a result of drug resistance, many infections prove refractory to a wide array of standard treatment protocols.

Therefore, new therapies for the treatment, prevention, management, and/or amelioration of respiratory tract infections and symptoms thereof are needed.

Activation of innate defences is essential to control pneumococcal infection. Toll-like receptor 2 (TLR2), TLR4 and TLR9 as well as the adaptor MyD88 participate in the early detection and clearance of pneumococcus in the lungs. The cytosolic receptors nucleotide-binding oligomerization domain (Nod) containing Nod1 and Nod2, have also been involved in the recognition of pneumococci. TLR signaling activates mucosal innate responses that culminate with the recruitment of phagocytes like polymorphonuclear neutrophils (PMN) and macrophages and the production of microbicidal agents. This process triggers rapid eradication of the pathogen by phagocytosis as well as extracellular killing. In MyD88-deficient animals *S. pneumoniae* is unable to intrinsically trigger any PMN recruitment into airways and animals have increased susceptibility to pneumonia. The contribution of TLR signaling in humans has been highlighted by a recent study showing that some MyD88 polymorphisms are associated with increased susceptibility to pneumococcal infection.

Modulating immunity by the activity of innate receptors is an emerging concept to elicit protective responses against infections. The rationale is to promote innate responses that greatly exceed in magnitude, quality and dynamic the innate response triggered by the pathogen itself. The effectiveness of TLR agonists for therapeutic treatment of infectious diseases has been demonstrated in several animal models, including models of respiratory tract infections (Brown, K. L., C. Cosseau, J. L. Gardy and R. E. Hancock 2007. Complexities of targeting innate immunity to treat infection. *Trends Immunol* 28:260-266.; Lembo, A., M. Pelletier, R. Iyer, M. Timko, J. C. Dudda, T. E. West, C. B. Wilson, A. M. Hajjar, and S. J. Skerrett. 2008. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. *J Immunol* 180:7574-7581; Romagne, F. 2007. Current and future drugs targeting one class of innate immunity receptors: the Toll-like receptors. *Drug Discov Today* 12:80-87). TLR5 senses bacterial flagellins that are the main constituent of flagella.

Various cells of the pulmonary tract including the epithelial cells express TLR5 but the modulation of the TLR5 signalling pathway has not yet been investigated for the treatment of respiratory tract infections.

5 **SUMMARY OF THE INVENTION:**

The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.

10 **DETAILED DESCRIPTION OF THE INVENTION:**

Streptococcus pneumoniae is a major cause of pneumonia in infants and the elderly. Innate defenses are essential to control pneumococcal infections and deficient responses can trigger disease in susceptible individuals. Here, the inventors showed that flagellin can locally activate innate immunity and thereby increase the resistance to acute pneumonia. Flagellin mucosal treatment improved *S. pneumoniae* clearance in the lungs and promoted increased survival to infection. In addition, lung architecture was fully restored after the treatment of infected mice, indicating that flagellin allows the re-establishment of steady state conditions. Using a flagellin mutant that is unable to signal through TLR5, they established that TLR5 signaling is essential for protection. In the respiratory tract, flagellin induced neutrophil infiltration into airways and upregulated the expression of genes coding for IL-6, TNF- α , CXCL1, CXCL2 and CCL20. Using depleting antibodies, they demonstrated that neutrophils are major effectors for protection. Further, they found that B and T cell-deficient SCID mice clear *S. pneumoniae* challenge to the same extent than immunocompetent animals suggesting that these cell populations are not required for flagellin-induced protection. In conclusion, the results emphasize that mucosal stimulation of innate immunity by a TLR not naturally engaged by *S. pneumoniae* can increase the potency to cure pneumococcal pneumonia. Moreover without wishing to be bound by any particular theory, the inventors believe that mucosal stimulation of innate immunity by TLR5 also represents a relevant way for the treatment of respiratory tract infections. For instance, microbial products like non-typeable *Haemophilus influenzae* lysates that are known to stimulate innate immunity by respiratory route are able to protect against various respiratory infections (Evans SE, Scott BL, Clement CG, Larson DT, Kontoyiannis D, Lewis RE, Lasala PR, Pawlik J, Peterson JW, Chopra AK, Klimpel G, Bowden G, Höök M, Xu Y, Tuvim MJ, Dickey BF. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am J Respir Cell Mol

Biol. 2010 ;42:40-50), including *S. pneumoniae* infections (Clement CG, Evans SE, Evans CM, Hawke D, Kobayashi R, Reynolds PR, Moghaddam SJ, Scott BL, Melicoff E, Adachi R, Dickey BF, Tuvim MJ. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. *Am J Respir Crit Care Med.* 2008 ;177:1322-30.). Such
5 respiratory infections include diseases that are induced by bacteria, viruses and fungi.

Therefore, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.

10 The term “respiratory tract infection” has its general meaning in the art and is intended to designated infections of the upper respiratory tract (e.g., nose, ears, sinuses, and throat) and lower respiratory tract (e.g., trachea, bronchial tubes, and lungs) induced by a live microorganism.

15 Examples of viruses which cause viral infections include, but are not limited to, retroviruses (e.g., human T-cell lymphotropic virus (HTLV) types I and II and human immunodeficiency virus (HIV)), herpes viruses (e.g., herpes simplex virus (HSV) types I and II, Epstein-Barr virus, HHV6-HHV8, and cytomegalovirus), arenaviruses (e.g., lassa fever virus), paramyxoviruses (e.g., morbillivirus virus, human respiratory syncytial virus, mumps,
20 hMPV, and pneumovirus), adenoviruses, bunyaviruses (e.g., hantavirus), comaviruses, filoviruses (e.g., Ebola virus), flaviviruses (e.g., hepatitis C virus (HCV), yellow fever virus, and Japanese encephalitis virus), hepadnaviruses (e.g., hepatitis B viruses (HBV)), orthomyoviruses (e.g., influenza viruses A, B and C and PIV), papovaviruses (e.g., papillomaviruses), picornaviruses (e.g., rhinoviruses, enteroviruses and hepatitis A viruses),
25 poxviruses, reoviruses (e.g., rotaviruses), togaviruses (e.g., rubella virus), and rhabdoviruses (e.g., rabies virus).

Examples of bacteria which cause bacterial respiratory tract infections include, but not limited to, the *Aquaspirillum* family, *Azospirillum* family, *Azotobacteraceae* family,
30 *Bacteroidaceae* family, *Bartonella* species, *Bdellovibrio* family, *Campylobacter* species, *Chlamydia* species (e.g., *Chlamydia pneumoniae*), *Clostridium*, *Enterobacteriaceae* family (e.g., *Citrobacter* species, *Edwardsiella*, *Enterobacter aerogenes*, *Erwinia* species, *Escherichia coli*, *Hafnia* species, *Klebsiella* species, *Morganella* species, *Proteus vulgaris*, *Providencia*, *Salmonella* species, *Serratia marcescens*, and *Shigella flexneri*), *Gardinella* family,

Haemophilus influenzae, Halobacteriaceae family, Helicobacter Family, Legionellaceae family, Listeria species, Methylococcaceae family, mycobacteria (e.g., Mycobacterium tuberculosis), Neisseriaceae family, Oceanospirillum family, Pasteurellaceae family, Pneumococcus species, Pseudomonas species, Rhizobiaceae family, Spirillum Family, Spirosomaceae family, Staphylococcus (e.g., methicillin resistant Staphylococcus aureus and Staphylococcus pyrogenes), Streptococcus (e.g., Streptococcus enteritidis, Streptococcus Fasciae, and Streptococcus pneumoniae), Vampirovibr Helicobacter Family, and Vampirovibrio family.

10 Examples of fungi which cause fungal infections include, but not limited to, Absidia species (e.g., Absidia corymbifera and Absidia ramosa), Aspergillus species, (e.g., Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans, Aspergillus niger, and Aspergillus terreus), Blastomyces dermatitidis, Candida species (e.g., Candida albicans, Candida glabrata, Candida kerr, Candida krusei, Candida parapsilosis, Candida
15 pseudotropicalis, Candida quillermondii, Candida rugosa, Candida stellatoidea, and Candida tropicalis), Coccidioides immitis, Conidiobolus species, Cryptococcus neoforms, Cunninghamella species, Histoplasma capsulatum, Mucorpusillus, Paracoccidioides brasiliensis, Pseudallescheria boydii, Pneumocystis carinii, Rhizopus species (e.g., Rhizopus arrhizus, Rhizopus oryzae, and Rhizopus Microspores), Saccharomyces species, and
20 Sporothrix schenckii.

In a particular embodiment, the respiratory tract infection according to the invention is a bacterial respiratory tract infection, more particularly a respiratory tract infection that results from bacteria that do not have flagella. Typically, bacteria that do not have flagella and cause
25 respiratory tract infection include *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Moraxella catarrhalis*, or *Mycoplasma pneumoniae*. Even more preferably, the respiratory tract infection according to the invention is a pneumococcal infection.

As used herein the term "toll-like receptor 5" or "TLR5" has its general meaning in the
30 art and is intended to mean a toll-like receptor 5 of any species, but preferably a human toll-like receptor 5. Upon activation, a TLR5 induces a cellular response by transducing an intracellular signal that is propagated through a series of signaling molecules from the cell surface to the nucleus. Typically, the intracellular domain of TLR5 recruits the adaptor protein, MyD88, which recruits the serine/threonine kinases IRAK (IRAK-1 and IRAK-4).

IRAKs form a complex with TRAF6, which then interacts with various molecules that participate in transducing the TLR signal. These molecules and other TLR5 signal transduction pathway components stimulate the activity of transcription factors, such as fos, jun and NF-kB, and the corresponding induction of gene products of fos-, jun- and NF-kB-regulated genes, such as, for example, IL-6, TNF- α , CXCL1, CXCL2 and CCL20.

As used herein, the term "TLR5 agonist" refers to a compound (natural or not) that selectively activates or increases normal signal transduction through TLR5. A TLR5 agonist can activate or increase normal signal transduction through TLR5 indirectly, for example, by modifying or altering the native conformation of TLR5 or a TLR5 ligand. The activities of signalling molecules that mediate the TLR5 signal, as well as molecules produced as a result of TLR5 activation are TLR5 activities that can be observed or measured. Therefore, a TLR5 activity includes recruitment of intracellular signaling molecules, as well as downstream events resulting from TLR5 activation, such as transcription factor activation and production of immunomodulatory molecules. A TLR5 cellular response mediates an innate immune system response in a subject because cytokines released by TLR5-expressing cells regulate other immune system cells to promote an immune response in a subject. Therefore, as used herein the term "TLR5-mediated response" is intended to mean the ability of TLR5 agonist to induce a TLR5-mediated cellular response. Exemplary TLR5-mediated cellular responses include activation of transcription factors such as fos, jun and NF-kB, production of cytokines and chemokines such as IL-6, TNF- α , CXCL1, CXCL2 and CCL20, and the stimulation of an immune response in a subject.

In one embodiment, the TLR5 agonist according to the invention is a low molecular weight agonist, e. g. a small organic molecule. The term "small organic molecule" refers to a molecule of a size comparable to those organic molecules generally used in pharmaceuticals. The term excludes biological macromolecules (e. g., proteins, nucleic acids, etc.). Preferred small organic molecules range in size up to about 5000 Da, more preferably up to 2000 Da, and most preferably up to about 1000 Da.

Alternatively, the TLR5 agonist according to the invention may consist in an antibody (the term including "antibody fragment"). In particular, the TLR5 agonist may consist in an antibody directed against TLR5, in such a way that said antibody activates the receptor.

Antibodies can be raised according to known methods by administering the appropriate antigen or epitope to a host animal selected, e.g., from pigs, cows, horses, rabbits, goats, sheep, and mice, among others. Various adjuvants known in the art can be used to enhance antibody production. Although antibodies useful in practicing the invention can be polyclonal, monoclonal antibodies are preferred. Monoclonal antibodies can be prepared and isolated using any technique that provides for the production of antibody molecules by continuous cell lines in culture. Techniques for production and isolation include but are not limited to the hybridoma technique; the human B-cell hybridoma technique; and the EBV-hybridoma technique. Alternatively, techniques described for the production of single chain antibodies (see, e.g., U.S. Pat. No. 4,946,778) can be adapted to produce anti-TLR5 single chain antibodies.

The TLR5 agonist useful in practicing the present invention also include anti-TLR5 antibody fragments including but not limited to F(ab')₂ fragments, which can be generated by pepsin digestion of an intact antibody molecule, and Fab fragments, which can be generated by reducing the disulfide bridges of the F(ab')₂ fragments. Alternatively, Fab and/or scFv expression libraries can be constructed to allow rapid identification of fragments having the desired specificity to TLR5.

Humanized antibodies and antibody fragments thereof can also be prepared according to known techniques. "Humanized antibodies" are forms of non-human (e.g., rodent) chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region (CDRs) of the recipient are replaced by residues from a hypervariable region of a non-human species (donor antibody) such as mouse, rat, rabbit or nonhuman primate having the desired specificity, affinity and capacity. In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FRs are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. Methods

for making humanized antibodies are described, for example, by Winter (U.S. Pat. No. 5,225,539) and Boss (Celltech, U.S. Pat. No. 4,816,397).

Then after raising antibodies as above described, the skilled man in the art can easily select those that are TLR5 agonists.

5

In another embodiment the TLR5 agonist is an aptamer. Aptamers are a class of molecule that represents an alternative to antibodies in term of molecular recognition. Aptamers are oligonucleotide or oligopeptide sequences with the capacity to recognize virtually any class of target molecules with high affinity and specificity. Such ligands may be isolated through Systematic Evolution of Ligands by EXponential enrichment (SELEX) of a random sequence library, as described in Tuerk C. and Gold L., 1990. The random sequence library is obtainable by combinatorial chemical synthesis of DNA. In this library, each member is a linear oligomer, eventually chemically modified, of a unique sequence. Possible modifications, uses and advantages of this class of molecules have been reviewed in Jayasena S.D., 1999. Peptide aptamers consists of a conformationally constrained antibody variable region displayed by a platform protein, such as *E. coli* Thioredoxin A that are selected from combinatorial libraries by two hybrid methods.

Then after raising aptamers directed against TLR5 as above described, the skilled man in the art can easily select those that are TLR5 agonists.

20

In another particular embodiment, the TLR5 agonist according to the invention is a polypeptide, and more particularly a flagellin polypeptide.

As used herein, the term "flagellin" is intended to mean the flagellin contained in a variety of Gram-positive or Gram-negative bacterial species. Non-limiting sources of flagellins include but are not limited to *Escherichia*, e.g., *E. coli*, *Enterobacter*, *Erwinia*, *Klebsiella*, *Proteus*, *Salmonella*, e.g., *Salmonella enterica* serovar *Typhimurium*, *Serratia*, e.g., *Serratia marcescans*, and *Shigella*, as well as Bacilli such as *B. subtilis* and *B. licheniformis*, *Pseudomonas* such as *P. aeruginosa*, and *Streptomyces*. These examples are illustrative rather than limiting. The amino acid sequences and nucleotide sequences of flagellins are publically available in the NCBI Genbank, see for example Accession Nos. AAL20871, NP_310689, BAB58984, AAO85383, AAA27090, NP_461698, AAK58560, YP_001217666, YP_002151351, YP_001250079, AAA99807, CAL35450, AAN74969, and BAC44986. The flagellin sequences from these and other species are intended to be

30

encompassed by the term flagellin as used herein. Therefore, the sequence differences between species are included within the meaning of the term.

The term "flagellin polypeptide" is intended to a flagellin or a fragment thereof that
5 retains the ability to bind and activate TLR5. Typically, the flagellin polypeptide according to the invention comprises the domains of flagellin involved in TLR5 signaling. The term "domain of flagellin" includes naturally occurring domain of flagellin and function conservative variants thereof. "Function conservative variants" are those in which a given amino acid residue in a protein or enzyme has been changed without altering the overall
10 conformation and function of the polypeptide, including, but not limited to, replacement of an amino acid with one having similar properties (such as, for example, polarity, hydrogen bonding potential, acidic, basic, hydrophobic, aromatic, and the like). Amino acids other than those indicated as conserved may differ in a protein so that the percent protein or amino acid sequence similarity between any two proteins of similar function may vary and may be, for
15 example, from 70 % to 99 % as determined according to an alignment scheme such as by the Cluster Method, wherein similarity is based on the MEGALIGN algorithm. A "function-conservative variant" also includes a polypeptide which has at least 60 % amino acid identity as determined by BLAST or FASTA algorithms, preferably at least 75 %, most preferably at least 85%, and even more preferably at least 90 %, and which has the same or substantially
20 similar properties or functions as the native or parent protein to which it is compared. The domains of flagellin that are involved in TLR5 signaling are well known in the art, see for example Smith et al. (2003) Nat. Immunol. 4: 1247-1253 (e.g., amino acids 78-129, 135-173 and 394-444 of *S. typhimurium* flagellin or homologs or modified forms thereof).

25 Examples of flagellin polypeptides include but are not limited to those described in U.S. Pat. Nos. 6,585,980; 6,130,082; 5,888,810; 5,618,533; and 4,886,748; U.S. Patent Publication No. US 2003/0044429 A1; and in the International Patent Application Publications n°WO 2008097016 and WO 2009156405.

30 An exemplary *E. coli* O157:H7 flagellin is SEQ ID NO:1. An exemplary *S. typhimurium* flagellin is SEQ ID NO:2 or SEQ ID NO:3. Amino acid sequences at least about 90%, at least about 95%, at least about 97%, at least about 98% or at least about 99% identical to SEQ ID NO: 1 SEQ ID NO:2 or SEQ ID NO:3 can be used as flagellin polypeptides according to the invention.

In another particular embodiment, the present encompasses use of the flagellin recombinant proteins described in the International Patent Application n°WO 2009156405.

Accordingly, a flagellin polypeptide of the invention may comprise : a) a N-terminal peptide having at least 90% amino acid identity with the amino acid sequence starting from the amino acid residue located at position 1 of SEQ ID NO:3 and ending at an amino acid residue selected from the group consisting of any one of the amino acid residues located at positions 99 to 173 of SEQ ID NO:3 ; and b) a C-terminal peptide having at least 90% amino acid identity with the amino acid sequence starting at an amino acid residue selected from the group consisting of any one of the amino acid residues located at positions 401 to 406 of SEQ ID NO:3 and ending at the amino acid residue located at position 494 of SEQ ID NO:3 , wherein : the said N-terminal peptide is directly linked to the said C-terminal peptide, or the said N-terminal peptide and the said C-terminal peptide are indirectly linked, one to the other, through a spacer chain. In another particular embodiment, said N-terminal peptide is selected from the group consisting of the amino acid sequences 1-99, 1-137, 1-160 and 1-173 of SEQ ID NO:3. In another embodiment, said C-terminal peptide is selected from the group consisting of the amino acid sequences 401- 494 and 406-494 of SEQ ID NO:3. In another embodiment, said N- terminal and C-terminal peptides consist of the amino acid sequences 1-173 and 401-494 of SEQ ID NO:3, respectively. In another embodiment, said N- terminal and C-terminal peptides consist of the amino acid sequences 1-160 and 406-494 of SEQ ID NO:3 , respectively. In another embodiment, said N- terminal and C-terminal peptides consist of the amino acid sequences 1-137 and 406-494 of SEQ ID NO:3 , respectively. In another embodiment, said N-terminal peptide and the said C-terminal peptide are indirectly linked, one to the other, through an intermediate spacer chain consisting of a NH₂-Gly-Ala-Ala-Gly-COOH (SEQ ID NO:4) peptide sequence. In another embodiment, the asparagine amino acid residue located at position 488 of SEQ ID NO:3 is replaced by a serine. In another embodiment, the flagellin polypeptide as above described comprises an additional methionine residue at the N-terminal end.

The flagellin polypeptide according to the invention may be recombinantly produced by recombinant cells that have been transfected with a nucleic acid that encodes its amino acid sequence and allows its effective production within the transfected cells.

The nucleic acid sequence encoding the flagellin polypeptide of the invention, may be inserted into a replicable vector for cloning (amplification of the DNA) or for expression. Various vectors are publicly available. The vector may, for example, be in the form of a plasmid, cosmid, viral particle, or phage. The appropriate nucleic acid sequence may be inserted into the vector by a variety of procedures. In general, DNA is inserted into an appropriate restriction endonuclease site(s) using techniques known in the art.

Vector components generally include, but are not limited to, one or more of a signal sequence if the sequence is to be secreted, an origin of replication, one or more marker genes, an enhancer element, a promoter, and a transcription termination sequence. Construction of suitable vectors containing one or more of these components employs standard ligation techniques that are known to the skilled artisan.

The flagellin polypeptides of the invention may be produced recombinantly not only directly, but also as a fusion polypeptide with a heterologous polypeptide, which may be a signal sequence or other polypeptide having a specific cleavage site at the N-terminus of the mature protein or peptide. In general, the signal sequence may be a component of the vector, or it may be a part of the DNA encoding the polypeptide of interest that is inserted into the vector. The signal sequence may be a prokaryotic signal sequence selected, for example, from the group of the alkaline phosphatase, penicillinase, Ipp, or heat-stable enterotoxin II leaders. For yeast secretion the signal sequence may be, e.g., the yeast invertase leader, alpha factor leader (including *Saccharomyces* and *Kluyveromyces* .alpha. -factor leaders, the latter described in U.S. Pat. No. 5,010,182), or acid phosphatase leader, the *C. albicans* glucoamylase leader, or the signal described in WO 90/13646. In mammalian cell expression, mammalian signal sequences may be used to direct secretion of the protein, such as signal sequences from secreted polypeptides of the same or related species, as well as viral secretory leaders.

Both expression and cloning vectors contain a nucleic acid sequence that enables the vector to replicate in one or more selected host cells. Such sequences are well known for a variety of bacteria, yeast, and viruses. The origin of replication from the plasmid pBR322 is suitable for most Gram-negative bacteria, the 2.mu. plasmid origin is suitable for yeast, and various viral origins (SV40, polyoma, adenovirus, VSV, or BPV) are useful for cloning vectors in mammalian cells.

Expression and cloning vectors will typically contain a selection gene, also termed a selectable marker. Typical selection genes encode proteins that (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate, or tetracycline, (b)

complement auxotrophic deficiencies, or (c) supply critical nutrients not available from complex media, e.g., the gene encoding D-alanine racemase for Bacilli.

An example of suitable selectable markers for mammalian cells are those that enable the identification of cells competent to take up the nucleic acid encoding the flagellin polypeptide of the invention such as DHFR or thymidine kinase. An appropriate host cell
5 when wild-type DHFR is employed is the CHO cell line deficient in DHFR activity, prepared and propagated as described by Urlaub et al., Proc. Natl. Acad. Sci. USA, 77: 4216 (1980). A suitable selection gene for use in yeast is the trp 1 gene present in the yeast plasmid YRp7. Stinchcomb et al., Nature, 282: 39 (1979); Kingsman et al., Gene, 7: 141 (1979); Tschemper
10 et al, Gene, 10: 157 (1980). The trp1 gene provides a selection marker for a mutant strain of yeast lacking the ability to grow in tryptophan, for example, ATCC No. 44076 or PEP4-1. Jones, Genetics, 85: 12 (1977).

Expression and cloning vectors usually contain a promoter operably linked to the nucleic acid sequence encoding the flagellin polypeptide to direct mRNA synthesis.
15 Promoters recognized by a variety of potential host cells are well known. Promoters suitable for use with prokaryotic hosts include the beta-lactamase and lactose promoter systems (Chang et al., Nature, 275: 615 (1978); Goeddel et al., Nature, 281 : 544 (1979)), alkaline phosphatase, a tryptophan (trp) promoter system (Goeddel, Nucleic Acids Res., 8:4057 (1980); EP 36,776), and hybrid promoters such as the tac promoter (deBoer et al., Proc. Natl.
20 Acad. Sci. USA, 80: 21 -25 (1983)). promoters for use in bacterial systems also will contain a Shine-Dalgarno (S. D.) sequence operably linked to the DNA encoding the flagellin polypeptide of the invention.

Examples of suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase (Hitzeman et al., J. Biol. Chem., 255: 2073 (1980))
25 or other glycolytic enzymes (Hess et al., J. Adv. Enzyme Reg., 7: 149 (1968); Holland, Biochemistry, 17: 4900 (1978)), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase.

30 Other yeast promoters that are inducible promoters having the additional advantage of transcription controlled by growth conditions are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein, glyceraldehyde-3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose utilization. Suitable vectors and promoters for

use in yeast expression are further described in EP 73,657. Nucleic acid of interest transcription from vectors in mammalian host cells is controlled, for example, by promoters obtained from the genomes of viruses such as polyoma virus, fowl pox virus (UK 2,211,504 published 5 Jul. 1989), adenovirus (such as Adenovirus 2), bovine papilloma virus, avian sarcoma virus, cytomegalovirus, a retrovirus, hepatitis-B virus, and Simian Virus 40 (SV40);
5 by heterologous mammalian promoters, e.g., the actin promoter or an immunoglobulin promoter; and by heat-shock promoters, provided such promoters are compatible with the host cell systems.

Transcription of a DNA encoding the flagellin polypeptide of the invention by higher
10 eukaryotes may be increased by inserting an enhancer sequence into the vector. Enhancers are cis-acting elements of DNA, usually about from 10 to 300 bp, that act on a promoter to increase its transcription. Many enhancer sequences are now known from mammalian genes (globin, elastase, albumin, α -fetoprotein, and insulin). Typically, however, one will use an enhancer from a eukaryotic cell virus. Examples include the SV40 enhancer on the late
15 side of the replication origin (bp 100-270), the cytomegalovirus early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovirus enhancers. The enhancer may be spliced into the vector at a position 5' or 3' to the sequence coding for polypeptides of interest, but is preferably located at a site 5' from the promoter.

Expression vectors used in eukaryotic host cells (yeast, fungi, insect, plant, animal,
20 human, or nucleated cells from other multicellular organisms) will also contain sequences necessary for the termination of transcription and for stabilizing the mRNA. Such sequences are commonly available from the 5' and, occasionally 3', untranslated regions of eukaryotic or viral DNAs or cDNAs. These regions contain nucleotide segments transcribed as polyadenylated fragments in the untranslated portion of the mRNA encoding the flagellin
25 polypeptide of the invention.

Still other methods, vectors, and host cells suitable for adaptation to the synthesis of the flagellin polypeptide of the invention in recombinant vertebrate cell culture are described in Gething et al., Nature, 293: 620-625 (1981); Mantei et al., Nature, 281 : 40-46 (1979); EP 1 17,060; and EP 1 17,058.

30 Selection and Transformation of Host Cells Host cells are transfected or transformed with expression or cloning vectors described herein for flagellin polypeptide production and cultured in conventional nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences.

The culture conditions, such as media, temperature, pH, and the like, can be selected by the skilled artisan without undue experimentation. In general, principles, protocols, and practical techniques for maximizing the productivity of cell cultures can be found in Mammalian Cell Biotechnology: A Practical Approach, M. Butler, ed. (IRL Press, 1991).

5 Methods of transfection are known to the ordinarily skilled artisan, for example, CaPO₄ treatment and electroporation. Depending on the host cell used, transformation is performed using standard techniques appropriate to such cells. The calcium treatment employing calcium chloride, as described in Sambrook et al., supra, or electroporation is generally used for prokaryotes or other cells that contain substantial cell-wall barriers. For
10 mammalian cells without such cell walls, the calcium phosphate precipitation method of Graham and van der Eb, Virology, 52:456-457 (1978) can be employed. General aspects of mammalian cell host system transformations have been described in U.S. Pat. No. 4,399,216. Transformations into yeast are typically carried out according to the method of Van Solingen et al., J. Bact, 130: 946 (1977) and Hsiao et al., Proc. Natl. Acad. Sci. (USA), 76: 3829
15 (1979). However, other methods for introducing DNA into cells, such as by nuclear microinjection, electroporation, bacterial protoplast fusion with intact cells, or polycations, e.g., polybrene or polyornithine, may also be used. For various techniques for transforming mammalian cells, see, Keown et al., Methods in Enzymology, 185: 527-537 (1990) and Mansour et al., Nature, 336: 348-352 (1988).

20 Suitable host cells for cloning or expressing the DNA in the vectors herein include prokaryote, yeast, or higher eukaryote cells.

Suitable prokaryotes include, but are not limited to, eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobacteriaceae such as *E. coli*. Various *E. coli* strains are publicly available, such as *E. coli* K12 strain MM294 (ATCC 31 ,446); *E. coli*
25 X1776 (ATCC 31 ,537); *E. coli* strain W3110 (ATCC 27,325); and K5772 (ATCC 53,635). Other suitable prokaryotic host cells include Enterobacteriaceae such as Escherichia, e.g., *E. coli*, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, e.g., *Salmonella typhimurium*, Serratia, e.g., *Serratia marcescans*, and Shigella, as well as Bacilli such as *B. subtilis* and *B. licheniformis* (e.g., *B. licheniformis* 41 P disclosed in DD 266,710 published 12 Apr. 1989),
30 Pseudomonas such as *P. aeruginosa*, and Streptomyces. These examples are illustrative rather than limiting.

Strain SIN41 of *Salmonella typhimurium* (fliC fljB), is particularly interesting for the production of flagellin polypeptides of the invention, since these prokaryotic host cells do not secrete any flagellins (Proc Natl Acad Sci U S A. 2001 ;98:13722-7). However flagellins are

secreted through specialized secretion system: the so called "Type III secretion system". Interestingly, strain SIN41 produces all components of the type III secretion system required for optimal flagellin secretion. Cloning sequence coding new flagellin peptides under *fliC* promoter enables secretion in large amounts of the flagellin polypeptides of interest in strain
5 SIN41.

Strain W3110 is also interesting because it is a common host strain for recombinant DNA product fermentations. Preferably, the host cell secretes minimal amounts of proteolytic enzymes. For example, strain W3110 may be modified to effect a genetic mutation in the genes encoding proteins endogenous to the host, with examples of such hosts including *E. coli*
10 W3110 strain 1A2, which has the complete genotype *tonA*; *E. coli* W3110 strain 9E4, which has the complete genotype *tonA ptr3*; *E. coli* W31 10 strain 27C7 (ATCC 55,244), which has the complete genotype *tonA ptr3 phoA E15 (argF-lac)169 degP ompT kan.sup.r*; *E. coli* W31 10 strain 37D6, which has the complete genotype *tona ptr3 phoA E15 (argF-lac)169 degP ompT rbs7 ilvG kan.sup.r*; *E. coli* W31 10 strain 40B4, which is strain 37D6 with a non-
15 kanamycin resistant *degP* deletion mutation; and an *E. coli* strain having mutant periplasmic protease disclosed in U.S. Pat. No. 4,946,783 issued 7 Aug. 1990. The *E. coli* strains MG1655, MG1655 AfimA-H or MKS12, a *fliD*- and *-f/m>A-/-*-deleted MG1655 strain are also interesting candidates for production of recombinant flagellins as secreted proteins (Nat Biotechnol. 2005; (4):475-81). Alternatively, in vitro methods of cloning, e.g., PCR or other
20 nucleic acid polymerase reactions, are suitable.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for vectors encoding the flagellin polypeptides according to the invention. *Saccharomyces cerevisiae* is a commonly used lower eukaryotic host microorganism.

Others include *Schizosaccharomyces pombe* (Beach and Nurse, Nature, 290: 140 [1981]; EP 139,383 published 2 May 1985); *Kluyveromyces* hosts (U.S. Pat. No. 4,943,529; Fler et al., Bio/Technology, 9: 968-975 (1991)) such as, e.g., *K. lactis* (MW98-8C, CBS683, CBS4574; Louvencourt et al., J. Bacterid., 737 [1983]), *K. fragilis* (ATCC 12,424), *K. bulgaricus* (ATCC 16,045), *K. wickeramii* (ATCC 24,178), *K. waltii* (ATCC 56,500), *K. drosophilum* (ATCC 36,906; Van den Berg et al., Bio/Technology, 8:135 (1990)), *K. thermotolerans*, and *K. marxianus*; *yarrowia* (EP 402,226); *Pichia pastoris* (EP 183,070; Sreekrishna et al., J. Basic Microbiol., 28: 265-278 [1988]); *Candida*; *Trichoderma reesia* (EP 244,234); *Neurospora crassa* (Case et al., Proc. Natl. Acad. Sci. USA, 76: 5259-5263 [1979]); *Schwanniomyces* such as *Schwanniomyces occidentalis* (EP 394,538 published 31

Oct. 1990); and filamentous fungi such as, e.g., Neurospora, Penicillium, Tolypocladium (WO 91/00357 published 10 Jan. 1991), and Aspergillus hosts such as *A. nidulans* (Ballance et al., Biochem. Biophys. Res. Commun., 112: 284-289 [1983]; Tilburn et al., Gene, 26: 205-221 [1983]; Yelton et al., Proc. Natl. Acad. Sci. USA, 81 : 1470-1474 [1984]) and *A. niger* 5 (Kelly and Hynes, EMBO J., 4: 475-479 [1985]). Methylophilic yeasts are suitable herein and include, but are not limited to, yeast capable of growth on methanol selected from the genera consisting of Hansenula, Candida, Kluyveromyces, Pichia, Saccharomyces, Torulopsis, and Rhodotorula.. Suitable host cells for the expression of nucleic acid encoding flagellin polypeptide of the invention are derived from multicellular organisms. Examples of 10 invertebrate cells include insect cells such as Drosophila S2 and Spodoptera Sf9, as well as plant cells. Examples of useful mammalian host cell lines include Chinese hamster ovary (CHO) and COS cells. More specific examples include monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture, Graham et al., J. Gen. Virol., 36: 59 (1977)); 15 Chinese hamster ovary cells/-DHFR(CHO, Urlaub and Chasin, Proc. Natl. Acad. Sci. USA, 77:4216 (1980)); mouse Sertoli cells (TM4, Mather, Biol. Reprod., 23:243-251 (1980)); human lung cells (W138, ATCC CCL 75); human liver cells (Hep G2, HB 8065); and mouse mammary tumor (MMT 060562, ATCC CCL51). The selection of the appropriate host cell is deemed to be within the skill in the art.

20

Flagellin polypeptide of the invention may be recovered from culture medium or from host cell lysates. If membrane-bound, it can be released from the membrane using a suitable detergent solution (e.g., TRITON- XTM. 100) or by enzymatic cleavage.

Cells employed in expression of nucleic acid encoding the flagellin polypeptide of the 25 invention can be disrupted by various physical or chemical means, such as freeze-thaw cycling, sonication, mechanical disruption, or cell-lysing agents. It may be desired to purify the polypeptide of interest from recombinant cell proteins or polypeptides. The following procedures are exemplary of suitable purification procedures: by fractionation on an ion-exchange column; ethanol precipitation; reverse phase HPLC; chromatography on silica or on 30 a cation-exchange resin such as DEAE; chromatofocusing; SDS-PAGE; ammonium sulfate precipitation; gel filtration using, for example, Sephadex G-75; Protein A Sepharose columns to remove contaminants such as IgG; and metal chelating columns to bind epitope-tagged forms of the flagellin polypeptide of the invention.

Various methods of protein purification may be employed and such methods are known in the art and described, for example, in Deutscher, Methods in Enzymology, 182 (1990); Scopes, Protein Purification: Principles and Practice (Springer-Verlag: New York, 1982). The purification step(s) selected will depend, for example, on the nature of the production process used and the particular flagellin polypeptide produced.

In a preferred embodiment, the flagellin polypeptide is purified from the supernatant of recombinant *S. Typhimurium* SIN41 (fliC fljB), as disclosed in Nempont et al. (Nempont, C. C., D.; Rumbo, M.; Bompard, C.; Villeret, V.; Sirard, J.C. 2008. Deletion of flagellin's hypervariable region abrogates antibody-mediated neutralization and systemic activation of TLR5-dependent immunity. J Immunol 181:2036-2043.). In particular, Salmonella were grown in Luria-Bertani (LB) broth for 6-18 hours at 37°C with agitation. The supernatant was filtered and saturated with 60% ammonium sulfate (Sigma Aldrich, USA). The precipitated materials were recovered by centrifugation, solubilization in 20mM Tris/HCl pH7.5 and then dialysis. The proteins were further purified by successive rounds of hydroxyapatite, anion exchange, and size exclusion chromatography (Bio-Rad Laboratories, USA; GE Healthcare, Sweden). Lastly, the proteins were depleted of lipopolysaccharide (LPS) using a polymyxin B column (Pierce, USA). Using the Limulus assay (Associates of Cape Cod Inc., USA), the residual LPS concentration was determined to be less than 30 pg LPS per µg recombinant flagellin.

In further embodiments, a flagellin polypeptide according to the invention may be purified by separation on an immunoaffinity chromatography substrate.

Said immunoaffinity chromatography substrate comprises anti-flagellin antibodies that have been immobilized thereon. By "anti-flagellin" antibodies, it is intended herein antibodies that bind to either a native flagellin or to a hypervariable region-deleted flagellin, including those encompassed by the present invention.

Preferably, the anti-flagellin antibodies consist of monoclonal antibodies, including mouse anti-flagellin antibodies.

In certain embodiments, a polypeptide of the invention may be synthesized through conventional techniques of chemical peptide synthesis.

For instance, the flagellin polypeptide sequence of the invention may be produced by direct peptide synthesis using solid-phase techniques.

In vitro protein synthesis may be performed using manual techniques or by automation. Automated synthesis may be accomplished, for instance, with an Applied Biosystems Peptide Synthesizer (Foster City, Calif.) using manufacturer's instructions.

5 Various portions of the polypeptide of interest may be chemically synthesized separately and combined using chemical or enzymatic methods to produce the full-length peptide of interest.

The present invention also relates to pharmaceutical compositions for use in a method for treating a respiratory tract infection comprising a TLR5 agonist according to the invention.

10 Typically, the TLR5 agonists according to the invention may be combined with pharmaceutically acceptable excipients, and optionally sustained-release matrices, such as biodegradable polymers, to form therapeutic compositions. "Pharmaceutically" or "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to a mammal, especially a human. A pharmaceutically acceptable carrier or excipient refers to a non-toxic
15 solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.

The pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include, but are not
20 limited to, parenteral, e.g., intravenous, intradermal, subcutaneous, oral, intranasal (e.g., inhalation), transdermal (e.g., topical), transmucosal, and rectal administration. In a specific embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous, subcutaneous, intramuscular, oral, intranasal, or topical administration to human beings. Typically, compositions for intravenous
25 administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic to ease pain at the site of the injection.

Preferably, the pharmaceutical composition of the invention is administered topically (i.e. in the respiratory tract of the subject). Therefore, the compositions can be formulated in
30 the form of an ointment, cream, transdermal patch, lotion, gel, spray, aerosol, solution, emulsion, or other form well-known to one of skill in the art. For non-sprayable topical dosage forms, viscous to semi-solid or solid forms comprising a carrier or one or more excipients compatible with topical application and having a dynamic viscosity preferably greater than water are typically employed. Suitable formulations include, without limitation,

solutions, suspensions, emulsions, creams, ointments, powders, liniments, salves, and the like, which are, if desired, sterilized or mixed with auxiliary agents (e.g., preservatives, stabilizers, wetting agents, buffers, or salts) for influencing various properties, such as, for example, osmotic pressure. Other suitable topical dosage forms include sprayable aerosol preparations
5 wherein the active ingredient, preferably in combination with a solid or liquid inert carrier, is packaged in a mixture with a pressurized volatile (e.g., a gaseous propellant, such as freon) or in a squeeze bottle. Moisturizers or humectants can also be added to pharmaceutical compositions and dosage forms if desired. Examples of such additional ingredients are well-known in the art.

10 If the method of the invention comprises intranasal administration of a composition, the composition can be formulated in an aerosol form, spray, mist or in the form of drops. In particular, prophylactic or therapeutic agents for use according to the present invention can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant (e.g., dichlorodifluoromethane,
15 trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas). In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges (composed of, e.g., gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

20 The method of the invention may comprise pulmonary administration, e.g., by use of an inhaler or nebulizer, of a composition formulated with an aerosolizing agent. See, e.g., U.S. Pat. Nos. 6,019,968, 5,985, 320, 5,985,309, 5,934,272, 5,874,064, 5,855,913, 5,290,540, and 4,880,078; and PCT Publication Nos. WO 92/19244, WO 97/32572, WO 97/44013, WO 98/31346, and WO 99/66903.

25 In a specific embodiment, the pharmaceutical composition of the invention is administered using Alkermes AIR™ pulmonary drug delivery technology (Alkermes, Inc., Cambridge, Mass.).

30 Accordingly, the invention provides a method of preventing, treating, managing, or ameliorating a respiratory tract infection or one or more symptoms thereof comprising administering a subject in need thereof with a therapeutically effective amount of a TLR5 agonist.

According to the invention, the term "subject" or "individual" to be treated is intended for a human or non-human mammal (such as a rodent (mouse, rat), a feline, a canine, or a primate) affected or likely to be affected with cancer. Preferably, the subject is a human.

5 The term "therapeutically effective amount" is meant for a sufficient amount of polypeptide or nucleic acid in order to treat cancer, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the polypeptide and pharmaceutical compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific
10 therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the polypeptide employed; the specific composition employed, the age, body weight, general health, sex and diet of the subject; the time of administration, route of administration, the duration of the treatment; the drugs used in combination or coincidental with the specific
15 polypeptide employed; and like factors well known in the medical arts.

The invention will be further illustrated by the following figures and examples. However, these examples and figures should not be interpreted in any way as limiting the scope of the present invention.

20

FIGURES:

FIGURE 1: Flagellin protects BALB/c mice against a lethal respiratory challenge with *S. pneumoniae*: BALB/c mice (n=8) were infected i.n. with 4×10^5 CFU of *S. pneumoniae* (Sp) serotype 1 in saline alone (black square), or supplemented with 1 μ g Flagellin (FliC, black circle) or supplemented with 1 μ g trypsin-digested flagellin (FliC/T, open circle). (A) Mice survival was daily monitored. Survival for FliC-treated group was statistically significant compared to saline group or FliC/T-treated group. Results are representative of 1 out of 3 experiments. (B) Mice were sacrificed 24 h after challenge and the
25 number of colony forming units (CFU) was determined in the lungs. Significant differences
30 between groups are marked with asterisk; $P < 0.05$ (*). Results are representative of 1 out of 3 experiments. Error bars represent the mean \pm Standard error of the mean (SEM).

FIGURE 2: TLR5 signaling is required for flagellin-mediated protection against *S. pneumoniae* infection: BALB/c mice (n=8) were infected i.n. with 4×10^5 CFU of *S. pneumoniae* (Sp) serotype 1 in saline alone (black square), or supplemented with 1 μ g FliC Δ 174-400 (black circle) or with 1 μ g FliC $_{\Delta$ 174-400/89-96* lacking TLR5-signaling motif (open circle). Mice survival was recorded daily. Survival for FliC Δ 174-400-treated group was statistically significant compared to untreated group or FliC $_{\Delta$ 174-400/89-96*-treated group ($P < 0.05$). Results are representative of 1 out of 2 experiments.

EXAMPLE:

10

Material & Methods

Bacterial preparation: *Streptococcus pneumoniae* serotype 1 (clinical isolate E1586) was obtained from the National Reference Laboratory - Ministry of Health, Uruguay (39). Working stocks were prepared as follows. Todd Hewitt Yeast Broth (THYB) (Sigma-Aldrich, St. Louis - MO, USA) was inoculated with fresh colonies of *S. pneumoniae* grown in blood-agar plates, and incubated at 37 °C until the culture reached OD_{600nm} of 0.7 - 0.9 units. Cultures were stored at -80°C in THYB + glycerol 12% (v/v) up to 3 months. For mouse infection, working stocks were thawed and washed with sterile physiological saline solution (saline) and diluted to the appropriate concentration. Number of bacteria in stocks was confirmed by plating serial dilutions onto blood agar plates.

Proteins: Native flagellin (FliC) from *Salmonella enterica* Serovar Typhimurium SIN22, or recombinant flagellins (FliC $_{\Delta$ 174-400 and FliC $_{\Delta$ 174-400/89-96*) were prepared as previously described (27). FliC $_{\Delta$ 174-400/89-96* carries aminoacids substitution (89-96) that prevents TLR5 signaling. All proteins contained low LPS amount (less than 30 pg LPS per μ g, determined with the Limulus assay). In some experiments, trypsin-hydrolyzed FliC (FliC/T) was used as a control. Native FliC was heated for 5 minutes at 65°C before use to ensure that proteins are mostly monomers. Unless specified, 1 μ g FliC, FliC/T, FliC $_{\Delta$ 174-400 or FliC $_{\Delta$ 174-400/89-96* was co-administered i.n. with the *S. pneumoniae* suspension. To exclude any direct effect of flagellin on bacterial viability, viable counts were determined prior and after incubation of *S. pneumoniae* with the same concentration of flagellin used for the *in vivo*

assay. There were no significant differences in the number of bacteria recovered after incubation with flagellin compared to control condition.

Animal infections: Female BALB/c, C57BL/6J and outbred NMRI strain (6-8 weeks
5 old) were obtained from the National Division of Veterinary Laboratories (Uruguay) or Janvier laboratories (France). Female SCID mice (C.B-17 SCID) were obtained from Institut Pasteur de Lille breeding facilities. These mice are characterized by the lack of B and T lymphocytes and agammaglobulinaemia. Animals were maintained in individually ventilated cages and handled in a vertical laminar flow cabinet (class II A2, ESCO, Pennsylvania-USA)
10 for infection. All experiments complied with current national and institutional regulations and ethical guidelines (CHEA – Universidad de la República, Uruguay and #A59107 – Institut Pasteur de Lille). Mice were anaesthetized by intraperitoneal (i.p.) injection of 2.2 mg Ketamine (Richmond-Vet Pharma, Bs. As. - Argentina) plus 0.11 mg Xylazine (Portinco, Montevideo - Uruguay) in a total volume of 200 µl or by inhalation of Isoflurane (Belamont, SAS, France) using an anaesthesia non-rebreathing system (DRE-Compact 150, DRE
15 Veterinary, Louisville – US). Bacteria and flagellins were administrated onto mice's nostrils in 20 to 50 µl of saline. Mice survival was recorded daily.

For depletion of granulocytes, 100 µg of anti-Gr-1 (RB6-8C5) or isotype control (HB152) were administered i.p. 24 h before i.n. challenge with *S. pneumoniae* (24). The anti-
20 Gr1 injection was found to deplete 96.8±1.2% PMNs in Bronchoalveolar Lavages (BAL) after flagellin intranasal treatment.

Determination of bacterial load in lungs and spleen: Lungs and spleen were collected at selected time points after intranasal challenge and homogenized with an
25 UltraTurrax homogenizer (IKA-Werke, Staufen-Germany). Viable counts were determined by plating serial dilutions onto blood-agar plates.

Quantitative RT-PCR (qRT-PCR): Lungs were homogenized in Trizol reagent (Invitrogen, California-USA) with UltraTurrax homogenizer and stored at -80 °C. RNA
30 extraction was performed according manufacturer's instructions. Prior to cDNA synthesis, 1 µg total RNA was treated with DNase-I (Invitrogen), and first strand complementary DNA (cDNA) synthesis was carried out using random primers (Invitrogen) and M-MLV reverse transcriptase (Invitrogen). Real-time PCR was performed using QuantiTect® SYBR® Green PCR Kit (Qiagen, Hilden-Germany) in a Rotor-Gene 6000 (Corbett, Sydney-Australia)

according to the following protocol: 15 min at 95°C followed by 40 cycles at 95°C for 15 sec and 60°C for 1 min. Primers were used in a final concentration of 0.9 μM. The expression of the gene of interest was normalized using β-actin as housekeeping gene. Results are presented as fold increase in mRNA levels compared to saline-treated group.

5

Determination of PMN infiltration into the airways and lungs: For bronchoalveolar lavages (BAL) sampling trachea was cannulated and 1 ml of PBS + 1 mM EDTA was instilled six times and recovered by gentle aspiration; this process was repeated twice. Cells were suspended in FACS-EDTA buffer (PBS, 0.1% azide, 1% bovine serum albumin from Sigma- Aldrich plus 5 mM EDTA). Lung cells were isolated after collagenase/DNAse treatment as previously described (34) and filtered through a 40 μm cell strainer. Immune cells were separated in a two-layered Percoll (Sigma-Aldrich) gradient. Briefly, cells were suspended in 35% isotonic Percoll solution, carefully placed on top of a 70% isotonic Percoll solution and centrifuged 30 min at 2600g and RT without brake. Top ring of cells corresponding mostly to epithelial cells was discarded and immune cells were recovered from the ring of cells closest to the 70% Percoll layer. Cells were filtered using a 100 μm cell strainer washed and stained for FACS analysis. Neutrophils were identified by FSC-SSC and positive staining for PE- or Alexa Fluor 647-conjugated anti-Ly-6G (clone 1A8), PerCP-Cy5.5-conjugated anti-Ly-6C (Clone HK1.4) or PE-conjugated anti-CD11b (clone M1/70) from BD Biosciences or BioLegend, California-USA. After fixation with PFA 4%, flow cytometry data acquisition was performed on a FACS Calibur Cytometer with CellQuest 3.3 software (BD Biosciences).

Histological analysis: Lungs were fixed in 4% formalin (Sigma-Aldrich) for 24 h and then embedded in paraffin. Lung blocks were sectioned at 5 μm using a Leica microtome (Leica Microsystems, Wetzlar-Germany) and adhered to silanized slides. Hematoxylin/eosin stained sections were analyzed using a Nikon Eclipse 80i microscope and a Nikon DS-Ri1 digital camera and processed using NIS-Elements BR 3.0 software by Laboratory Imaging.

Statistical analysis: Log-rank (Mantel-Cox) test was performed for analysis of survival curves. For comparison between two groups Mann-Whitney test was performed. *P* values <0.05 were considered significant in all cases. Statistical analysis was carried out using GraphPad Prism program (GraphPad Software, San Diego California USA).

Results

Intranasal delivery of flagellin protects mice against a lethal challenge with *S.*

5 *pneumoniae*: We first determined the minimal dose of *S. pneumoniae* that causes 100% mortality in BALB/c mice upon intranasal (i.n.) administration. Animals were infected with increasing doses of a clinical isolate of *S. pneumoniae* serotype 1 and survival was assessed daily. We defined 4×10^5 CFU as the minimal lethal dose (MLD) that kills all animals within 72 to 120 h.

10 The capacity of flagellin to control pneumococcal pneumonia was then assessed by comparing the survival of mice challenged intranasally with *S. pneumoniae* to mice instilled with flagellin (FliC) and *S. pneumoniae*. As a control, mice were also challenged with *S. pneumoniae* and flagellin previously hydrolyzed with trypsin (FliC/T). As shown in Figure 1A, FliC-treated mice had a survival rate of 75%, while untreated or FliC/T-treated animals
15 died within 3 to 4 days after challenge. The protection induced by flagellin ranged from 75 to 100% between different independent experiments. Co-administration of flagellin with *S. pneumoniae* resulted within 24 h in an 80-fold reduction of bacterial counts in the lungs as compared with animals that received *S. pneumoniae* alone (Figure 1B). We also evaluated whether flagellin could exert a protective response against pneumococcal infection when
20 administered before and after the infection. All animals receiving flagellin intranasally 12 to 24 h before pneumococcal challenge survived, while all control mice died by day 4. Moreover, 100% protection was also achieved when flagellin was administered 24 h after the challenge. Therefore, flagellin shows prophylactic and therapeutic effects in pneumococcal pneumonia.

25 The capacity of flagellin to induce protection was also assessed in C57BL/6 and the outbred strain NMRI. The MLD of *S. pneumoniae* serotype 1 was found to be 2×10^6 CFU for both strains, and flagellin-mediated protection was evaluated with 5xMLD. Administration of flagellin 12 h before bacterial challenge induced 80% protection in C57BL/6 mice; similarly, 100% protection was achieved in NMRI animals when flagellin was administered 32 h to 6 h
30 before challenge. Flagellin was also protective when co-administered with *S. pneumoniae* in C57BL/6 and NMRI strains, although to a lower extent (40%). Altogether, these results show that flagellin treatment is protective in different mouse strains.

We next addressed whether TLR5 signaling is necessary for the protection elicited by flagellin treatment. For this, we used the recombinant flagellins FliC $_{\Delta 174-400}$ and FliC $_{\Delta 174-400/89-96^*}$ (27). FliC $_{\Delta 174-400}$ has the same capacity to promote mucosal TLR5 signaling as native flagellin, whereas FliC $_{\Delta 174-400/89-96^*}$ carries mutations that prevents TLR5 signaling. Whereas
5 all mice that received FliC $_{\Delta 174-400}$ and *S. pneumoniae* survived the challenge, none of those receiving the mutant FliC $_{\Delta 174-400/89-96^*}$ did so (Figure 2). These results strongly suggest that TLR5 signaling is required for protection.

**Flagellin treatment promotes pro-inflammatory gene expression and exacerbates
10 transient cellular infiltration into the lungs during pneumococcal pneumonia:** We then analyzed whether flagellin treatment modify the lung transcriptional response to pneumococcal infection. Mice were challenged with *S. pneumoniae* or with *S. pneumoniae* plus flagellin as before. Another group received flagellin alone as control. Twenty four hours after treatment and infection, lungs were harvested to analyze the expression of selected genes
15 by qRT-PCR. Administration of flagellin alone or in combination with *S. pneumoniae* provoked a dramatic increase in *Cxcl1*, *Cxcl2* and *Ccl20* mRNA levels as compared to pneumococcal challenge. Flagellin treatment also increased expression of *Tnf*; although the difference was consistent, it was not statistically significant. Expression of *Il6* was increased in animals that were challenged and treated with flagellin but not in those that received
20 flagellin or *S. pneumoniae* alone suggesting a synergistic effect between flagellin and pneumococcal infection on *Il6* expression. mRNA levels of *Tgfb1*, *Il17a*, *Il17f*, *Il23* and *Il4* genes remained unchanged among all groups compared to mock animals.

To assess if expression of proinflammatory genes correlated with inflammation and cellular infiltration into the airways, we performed the histological analysis of lung tissue
25 obtained 24 h after flagellin-treatment and infection. *S. pneumoniae* induced moderate cellular infiltration restricted to certain bronchioles and some perivascular areas close to these bronchioles. On the contrary flagellin treatment, alone or together with the pneumococci, induced edema, and massive infiltration of cells affecting not only perivascular and peribroncheal regions but also some areas of the surrounding lung parenchyma. Remarkably,
30 at day 7 lungs from mice that received flagellin and pneumococci showed complete resolution of the inflammation with no apparent cellular infiltration or edema. These results suggest that flagellin induces a strong but transient inflammatory response that promotes the clearance of bacteria, without causing permanent alteration of lung morphology or function.

Flagellin-induced protection requires Gr-1 expressing cells but is independent of B and T lymphocytes: Neutrophils recruitment into the airways is a landmark of both pneumococcal infection and nasal flagellin treatment and here we showed that flagellin treatment and infection activated expression of genes involved in neutrophil recruitment. Thus, we aimed at comparing the kinetics of neutrophils infiltration in animals challenged with *S. pneumoniae* and either treated or not with flagellin. BAL and lungs were collected at different time points after challenge and stained with an anti-Ly6G antibody. Pneumococcal challenge induced recruitment of PMN in all animals. However, mice treated with flagellin at the time of the challenge showed a more rapid and pronounced infiltration of PMN into the airways as compared with mice challenged with *S. pneumoniae* alone. At 24 h, PMN infiltration peaked whatever the groups, and the difference between groups was maximal. However, by 48 hours the numbers of PMN were no longer significantly different between groups. Thus, co-administration of flagellin with pneumococcus promoted a rapid and transient recruitment of high number of neutrophils into the airways.

Subsequently, we determined whether neutrophils were critical for the flagellin-mediated protection. For this purpose, animals were injected i.p. with a monoclonal antibody specific for granulocyte receptor-1 (Gr-1 or Ly6G/Ly6C) or isotype control antibody 24 h before challenge. Animals that received isotype control and were treated with FliC survived to challenge. In contrast, anti-Gr-1 treatment depleted >95% neutrophils from the airways and abrogated flagellin-mediated protection against *S. pneumoniae*. These results showed that Gr-1-expressing cells, likely PMN, are critical effectors of flagellin-induced protection in pneumococcal infection.

As B and T lymphocytes have been involved in the early phase of pneumococcal infection, we evaluated their role in flagellin-induced protection. SCID mice (deficient for antibodies, B and T cells) as well as immunocompetent BALB/c mice were challenged with 2×10^7 CFU of *S. pneumoniae* or *S. pneumoniae* with flagellin. Lungs and spleen were collected 36 h after infection to determine bacterial counts. Flagellin co-administration promoted clearance of bacteria in the lungs of SCID mice to a similar extent than in BALB/c mice. Both SCID and BALB/c mice also showed lower bacterial counts in the spleen upon flagellin treatment meaning that they were able to control not only local, but also systemic infection. SCID mice recruited similar numbers of PMN into the lungs and alveolar spaces 16 h upon instillation of flagellin when compared to BALB/c mice. In summary, these results

show that Gr-1-expressing cells require neither B cells nor T lymphocytes to trigger flagellin-induced protection.

Discussion:

5

Innate immunity is essential for controlling pneumococcal infection as shown by TLR as well as MyD88 requirement to prevent early colonization of the respiratory tract by *S. pneumoniae* (Albiger, B., Sandgren A., Katsuragi H., Meyer-Hoffert U., Beiter K., Wartha F., Hornef M., Normark S. and Normark B. H. 2005. Myeloid differentiation factor 88-dependent signalling controls bacterial growth during colonization and systemic pneumococcal disease in mice. *Cell Microbiol* 7:1603-1615.; Khan, A. Q., Q. Chen, Z.-Q. Wu, J. C. Paton, and C. M. Snapper. 2005. Both innate immunity and type 1 humoral immunity to *Streptococcus pneumoniae* are mediated by MyD88 but differ in their relative levels of dependence on Toll-Like Receptor 2. *Infect. Immun.* 73:298-307.). Immune response to airway pneumococcal infection is characterized by a great and brisk recruitment of neutrophils into the lungs, and phagocytic killing of pneumococcus by PMN is considered a major defense mechanism. Nevertheless, *S. pneumoniae* can evade host's innate defenses by inhibiting or delaying complement deposition and respiratory burst of phagocytes. Hence, the neutrophil influx is often ineffective in clearing the infection until serotype-specific antibodies are produced and bypass complement deposition inhibition enhancing opsono-phagocytosis. In this study we assessed whether exogenous administration of an agonist of a TLR not naturally engaged by *S. pneumoniae*, namely TLR5 agonist flagellin, could strength innate immunity to control acute respiratory pneumococcal infection. We found that local administration of flagellin promoted survival of mice challenged with a lethal dose of *S. pneumoniae* serotype 1 by enhancing local and systemic bacterial clearance. Flagellin treatment was effective when performed before, during and after infection establishment in the BALB/c, C57BL/6 and NMRI mice.

It has been demonstrated that in vivo administration of flagellin upregulates the expression of proinflammatory cytokines. Here we show that coadministration of flagellin at the time of *S. pneumoniae* challenge also upregulates the expression of the PMN-specific chemokine/activator genes *Cxcl1* and *Cxcl2* and also *Tnf* and *Ccl20* in the lungs whereas *S. pneumoniae* alone was poorly inducing these genes. In agreement with the chemokine and cytokine expression profile, analysis of lung tissue sections showed a massive infiltration of cells in the peribroncheal and perivascular regions that was more pronounced in the lungs of

flagellin-treated animals than in infected non-treated animals. Noteworthy, despite the pronounced inflammatory response induced by flagellin, lung tissue was fully recovered by day 7, while untreated animals died of infection. The analysis of BAL samples suggested that administration of the TLR5 agonist at the time of pneumococcal challenge induced accelerated and more pronounced PMN recruitment. PMN infiltration was transient, peaked at 24 h and regressed to steady state levels at 40 h. Depletion of Gr-1-expressing cells, most likely PMN, abolished the protection demonstrating that these cells are necessary for controlling pneumococcal lung infection. The self-limiting nature of the flagellin-mediated inflammatory response is a very relevant finding since exacerbated inflammation could be associated to failure of lung barrier and function. The molecular mechanisms controlling TLR5 response do not only upregulate pro-inflammatory genes but also trigger response termination. Therefore, flagellin mucosal treatment could be considered as a therapy against pneumococcal pneumonia enhancing neutrophil infiltration and concurrent limitation of inflammation that merits further evaluation in clinical trials.

Besides PMN, several studies have also reported that T and B lymphocytes as well as natural antibodies may play an important role in the early control of pneumococcal pneumonia. It was showed that T lymphocytes accumulate in zones of peribroncheal inflammation at early stages of the immune response and are involved in the defense against pneumococcus since MHC class II-deficient mice lacking CD4⁺ T cells are more susceptible to infection compared to their wild type counterparts. It was showed that CD19-deficient mice, which have impaired development of B1a cells and natural antibody production, have increased susceptibility to pneumococcal infection. However, the results presented here show that neither T nor B cells are required for flagellin-induced local and systemic clearance of bacteria. Taken together, our results strongly suggest that changing the PMN dynamic results in effective killing of the pneumococci, even in the absence of B and T lymphocytes.

Our results also showed that TLR5 signaling is required for the protection induced by flagellin. In the airways, TLR5 is expressed by alveolar macrophages and epithelial cells, suggesting that these resident cells may be key players in the induction of protective innate defenses against *S. pneumoniae* upon flagellin treatment. In line with this, recent studies suggested that the airway epithelium is the TLR5-activated tissue involved in chemokine production and PMN recruitment in response to flagellated bacteria. On the other hand murine neutrophils express TLR5, thus TLR5 signaling may also directly activate PMN and enhance their *S. pneumoniae* killing capacity. In a similar fashion, it was previously established that

heat killed *Haemophilus influenzae* can specifically increase PMN capacity to kill pneumococcus in a Nod1-dependent manner.

Current therapies for prophylaxis and treatment of *S. pneumoniae* infection have limitations in preventing or curing pneumococcal disease, thus new strategies of immune-
5 intervention are still required. Several reports have shown that administration of bacterial lysates and whole heat killed bacteria stimulate protective responses against infection. However, the undefined nature of these preparations is usually a problem when designing drugs for human use. Our results showed that local stimulation with a single and well
10 characterized molecule, specifically flagellin, is sufficient for augmenting lung innate immune defenses and control pneumococcal pneumonia, highlighting the benefits of using Microbe-Associated Molecular Patterns as the basis for developing antimicrobial therapies.

REFERENCES:

15 Throughout this application, various references describe the state of the art to which this invention pertains.

CLAIMS

1. A TLR5 agonist for use in a method for treating a *Streptococcus pneumoniae* respiratory tract infection, wherein said TLR5 agonist is a flagellin polypeptide.
2. The TLR5 agonist for use according to claim 1, wherein said flagellin polypeptide is isolated from a bacterium selected from the group consisting of Escherichia, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, Serratia, Shigella, Bacilli, Pseudomonas, and Streptomyces.
3. The TLR5 agonist for use according to claim 2, wherein said Escherichia is *E. coli*.
4. The TLR5 agonist for use according to claim 2, wherein said Salmonella is *Salmonella enterica serovar Typhimurium*.
5. The TLR5 agonist for use according to claim 2, wherein said Serratia is *Serratia marcescans*.
6. The TLR5 agonist for use according to claim 2, wherein said Bacilli is *B. subtilis* or *B. licheniformis*.
7. The TLR5 agonist for use according to claim 2, wherein said Pseudomonas is *P. aeruginosa*.
8. The TLR5 agonist for use according to any one of claims 1 to 7, wherein the amino acid sequence of said flagellin polypeptide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; or is an amino acid sequence at least 90%, at least 95%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 1, SEQ ID NO:2 or SEQ ID NO:3, said flagellin polypeptide having TLR5 agonist activity.
9. The TLR5 agonist for use according to any one of claims 1 to 7, wherein said flagellin polypeptide comprises : a) a N-terminal peptide having at least 90% amino acid identity with the amino acid sequence starting from the amino acid residue located at position 1 of SEQ ID NO:3 and ending at an amino acid residue selected from the group consisting of any one of the amino acid residues located at positions 99 to 173 of SEQ ID NO:3; and b) a C-terminal peptide having at least 90% amino

acid identity with the amino acid sequence starting at an amino acid residue selected from the group consisting of any one of the amino acid residues located at positions 401 to 406 of SEQ ID NO:3 and ending at the amino acid residue located at position 494 of SEQ ID NO:3, wherein : the said N-terminal peptide is directly linked to the said C-terminal peptide, or the said N-terminal peptide and the said C-terminal peptide are indirectly linked, one to the other, through a spacer chain, said flagellin polypeptide having TLR5 agonist activity.

10. The TLR5 agonist for use according to claim 9, wherein said N-terminal peptide is selected from the group consisting of the amino acid sequences 1-99, 1-137, 1-160 and 1-173 of SEQ ID NO:3.
11. The TLR5 agonist for use according to claim 9 or 10, wherein said C-terminal peptide is selected from the group consisting of the amino acid sequences 401- 494 and 406-494 of SEQ ID NO:3.
12. The TLR5 agonist for use according to any one of claims 9 to 11, wherein said N-terminal and C-terminal peptides consist of the amino acid sequences 1-173 and 401-494 of SEQ ID NO:3, respectively.
13. The TLR5 agonist for use according to any one of claims 9 to 11, wherein said N-terminal and C-terminal peptides consist of the amino acid sequences 1-160 and 406-494 of SEQ ID NO:3, respectively.
14. The TLR5 agonist for use according to any one of claims 9 to 11, wherein said N-terminal and C-terminal peptides consist of the amino acid sequences 1-137 and 406-494 of SEQ ID NO:3, respectively.
15. The TLR5 agonist for use according to any one of claims 9 to 14, wherein said N-terminal peptide and the said C-terminal peptide are indirectly linked, one to the other, through an intermediate spacer chain consisting of a NH₂-Gly-Ala-Ala-Gly-COOH (SEQ ID NO:4) peptide sequence.
16. The TLR5 agonist for use according to any one of claims 9 to 15, wherein the asparagine amino acid residue located at position 488 of SEQ ID NO:3 is replaced by a serine.

17. The TLR5 agonist for use according to any one of claims 9 to 16, wherein said flagellin polypeptide comprises an additional methionine residue at the N-terminal end.
18. The TLR5 agonist for use according to any one of claims 1 to 17, which is formulated for a topical administration.
19. The TLR5 agonist for use according to claim 18, which is formulated in an aerosol form, spray, mist or in the form of drops.
20. The TLR5 agonist for use according to any one of claims 1 to 19, wherein said TLR5 agonist is formulated for intranasal administration or pulmonary administration.
21. Use of a TLR5 agonist for treating a *Streptococcus pneumoniae* respiratory tract infection, wherein said TLR5 agonist is a flagellin polypeptide.
22. Use of a TLR5 agonist for the manufacture of a medicament for treating a *Streptococcus pneumoniae* respiratory tract infection, wherein said TLR5 agonist is a flagellin polypeptide.
23. The use according to claim 21 or 22, wherein said flagellin polypeptide is isolated from a bacterium selected from the group consisting of Escherichia, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, Serratia, Shigella, Bacilli, Pseudomonas, and Streptomyces.
24. The use according to claim 23, wherein said Escherichia is *E. coli*.
25. The use according to claim 23, wherein said Salmonella is *Salmonella enterica* serovar *Typhimurium*.
26. The use according to claim 23, wherein said Serratia is *Serratia marcescans*.
27. The use according to claim 23, wherein said Bacilli is *B. subtilis* or *B. licheniformis*.
28. The use according to claim 23, wherein said Pseudomonas is *P. aeruginosa*.

29. The use according to any one of claims 21 to 28 wherein the amino acid sequence of said flagellin polypeptide is selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3; or is an amino acid sequence at least 90%, at least 95%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 1, SEQ ID NO:2 or SEQ ID NO:3, said flagellin polypeptide having TLR5 agonist activity.
30. The use according to any one of claims 21 to 28, wherein said flagellin polypeptide comprises : a) a N-terminal peptide having at least 90% amino acid identity with the amino acid sequence starting from the amino acid residue located at position 1 of SEQ ID NO:3 and ending at an amino acid residue selected from the group consisting of any one of the amino acid residues located at positions 99 to 173 of SEQ ID NO:3; and b) a C-terminal peptide having at least 90% amino acid identity with the amino acid sequence starting at an amino acid residue selected from the group consisting of any one of the amino acid residues located at positions 401 to 406 of SEQ ID NO:3 and ending at the amino acid residue located at position 494 of SEQ ID NO:3, wherein : the said N-terminal peptide is directly linked to the said C-terminal peptide, or the said N-terminal peptide and the said C-terminal peptide are indirectly linked, one to the other, through a spacer chain, said flagellin polypeptide having TLR5 agonist activity.
31. The use according to claim 30, wherein said N-terminal peptide is selected from the group consisting of the amino acid sequences 1-99, 1-137, 1-160 and 1-173 of SEQ ID NO:3.
32. The use according to claim 30 or 31, wherein said C-terminal peptide is selected from the group consisting of the amino acid sequences 401-494 and 406-494 of SEQ ID NO:3.
33. The use according to any one of claims 30 to 32, wherein said N- terminal and C-terminal peptides consist of the amino acid sequences 1-173 and 401-494 of SEQ ID NO:3, respectively.

34. The use according to any one of claims 30 to 32, wherein said N- terminal and C-terminal peptides consist of the amino acid sequences 1-160 and 406-494 of SEQ ID NO:3, respectively.
35. The use according to any one of claims 30 to 32, wherein said N- terminal and C-terminal peptides consist of the amino acid sequences 1-137 and 406-494 of SEQ ID NO:3, respectively.
36. The use according to any one of claims 30 to 35, wherein said N-terminal peptide and the said C-terminal peptide are indirectly linked, one to the other, through an intermediate spacer chain consisting of a NH₂-Gly-Ala-Ala-Gly-COOH (SEQ ID NO:4) peptide sequence.
37. The use according to any one of claims 30 to 36, wherein the asparagine amino acid residue located at position 488 of SEQ ID NO:3 is replaced by a serine.
38. The use according to any one of claims 30 to 37, wherein said flagellin polypeptide comprises an additional methionine residue at the N-terminal end.
39. The use according to any one of claims 21 to 38, wherein said TLR5 is formulated for a topical administration.
40. The use according to claim 39, wherein said TLR5 is formulated in an aerosol form, spray, mist or in the form of drops.
41. The use according to any one of claims 21 to 40, wherein said TLR5 agonist is formulated for intranasal administration or pulmonary administration.

1/2




Figure 1

2/2




Figure 2